High-Dose Neuroleptics and Neuroleptic Rotation for Agitated Delirium Near the End of Life

Paul B. Bascom*, Jessica L. Bordley, Andrew J. Lawton

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Reason for the study: Agitated delirium presents unique challenges for hospice and palliative care clinicians. Haloperidol, the recommended neuroleptic, may be ineffective at low dose, or poorly tolerated at higher doses.

Main Findings: This article reports on two patients with refractory agitated delirium. Both developed extrapyramidal symptoms from haloperidol and required rotation to an alternate neuroleptic. Patient #1 received 2000 mg/day oral chlorpromazine. Patient #2 received greater than 200 mg/day sublingual olanzapine. Control of agitation was achieved, though the doses were substantially higher than has previously reported in the literature. Each patient experienced considerable sedation, though this was an acceptable side effect for the family. Each patient was transferred from the acute care hospital to a location of family preference. There they died within a week of transfer.

Conclusions: Agitated delirium is a palliative care emergency. High doses of neuroleptic medications, with rotation to an alternate neuroleptic when side effects occur with standard haloperidol, may effectively palliate agitated delirium. This remedy can provide the patient with a peaceful dying in a place of their choosing.

Original languageEnglish (US)
Pages (from-to)808-811
Number of pages4
JournalAmerican Journal of Hospice and Palliative Medicine
Volume31
Issue number8
DOIs
StatePublished - Dec 10 2014

Keywords

  • agitated delirium
  • chlorpromazine
  • end-of-life care
  • olanzapine
  • palliative sedation
  • terminal delirium

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'High-Dose Neuroleptics and Neuroleptic Rotation for Agitated Delirium Near the End of Life'. Together they form a unique fingerprint.

Cite this